High and Low Dose Oral Sesame Immunotherapy - Comparison of Efficacy and Safety
Overview
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Medical University of Warsaw
- Enrollment
- 40
- Locations
- 1
- Primary Endpoint
- Tolerance of sesame
Overview
Brief Summary
In this trial the investigators aim to assess the effectiveness and safety of oral immunotherapy with sesame protein in high and low dose (300mg versus 1200mg) in children with sesame allergy.
Detailed Description
Sesame allergy is an important global clinical problem affecting 0,2-0,8% population. In food allergy, allergen avoidance and emergency treatment are still therapeutic hallmarks. Oral and sublingual allergen-specific immunotherapies have been provided as a new approach to managing food allergy. The main goal of oral immunotherapy is to obtain the desensitization to food. The oral immunotherapy (OIT) is considered as safe and highly effective, according to current research. In addition, this type of therapy reduce the influence of food allergy in patient's live.
Children 4 to 17 years old with sesame allergy will be enrolled into study. Skin prick test with condiment made from toasted ground hulled sesame and open oral food challenge (OOFC) will be performed at the baseline and at the end of procedure. Blood will be analyzed for specific IgE, IgG4 levels and basophil activation test before and after OIT. OIT will consisted of two parts: dosage increase phase and maintenance phase. The Participants will be randomized (1:1) to receive sesame OIT with maintenance dose of 300 mg or 1200 mg sesame protein.
In the dosage increase phase, the dose of condiment made from toasted ground hulled sesame will be gradually increased every two weeks and administrated to a child during hospitalization (1-day procedure). Precondition to increase of dose is good tolerance of previous portion of condiment made from toasted ground hulled sesame. The maximum time frame for this phase is 14 months.
After achieving tolerance, immunotherapy will be continued for 3 months in maintenance phase, with dose 300mg or 1200 mg sesame protein. Maintenance dose is determined by random patients' assignment to one from study's .
After 3 months (12 weeks +/-2 weeks) of maintenance dose the final OOFC and evaluation of desensitization of sesame protein will be performed. Confirmation of the total desensitization to sesame is the tolerance of a single dose of 4000 mg sesame protein.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 4 Years to 17 Years (Child)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •medical history of sesame allergy,
- •IgE-mediated sesame allergy confirmed as positive skin prick tests with sesame allergens (diameter of the wheal greater than 3mm) and/or specific IgE level greater than 0.35 kilo units of Allergen per liter (kUA/l) (UniCAP method),
- •reaction to sesame protein during OOFC (maximum dose 4000g),
- •signed Informed Consent by parent/legal guardian and patient aged \>16 years old,
- •patient's/caregivers' cooperation with researcher.
Exclusion Criteria
- •no confirmed sesame allergy,
- •negative oral food challenge with sesame protein (maximum dose 4000g),
- •severe asthma,
- •uncontrolled mild/moderate asthma: forced expiratory volume at one second (FEV1)\<80% (under
- •percentile), FEV1/forced vital capacity (FVC)\<75% (under
- •percentile), hospitalization due to asthma exacerbation within last 12 months,
- •current oral/sublingual/subcutaneous immunotherapy with other allergen,
- •eosinophilic gastroenteritis,
- •a history of severe recurrent anaphylaxis episodes,
- •chronic diseases requiring continuous treatment, including heart disease, epilepsy, metabolic diseases, diabetes,
Outcomes
Primary Outcomes
Tolerance of sesame
Time Frame: Up to 16 months after starting oral immunotherapy
Proportion of participants who tolerate the single dose of 4000mg sesame protein
Secondary Outcomes
- Skin prick test (SPT)(Up to 16 months after starting oral immunotherapy)
- Adverse event(Up to 16 months after starting oral immunotherapy)
- Basophil activation test(Up to 16 months after starting oral immunotherapy)
- Laboratory data(Up to 16 months after starting oral immunotherapy)
- Desensitization dose(Up to 16 months after starting oral immunotherapy)